Therapeutically active compounds and their methods of use

Abstract

Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

1 - 48 . (canceled) 
     
     
         49 . A tablet comprising a pharmaceutically acceptable carrier and a crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, wherein the crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 7.5, 9.3, 14.5, 18.8, 21.3, and 24.8°±0.2°. 
     
     
         50 . The tablet of  claim 49 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially similar to  FIG. 5 . 
     
     
         51 . The tablet of  claim 49 , wherein the tablet comprises 25, 50, 100 or 150 mg equivalent strength of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol. 
     
     
         52 . The tablet of  claim 49 , wherein the tablet comprises 100 mg equivalent strength of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol. 
     
     
         53 . A method of treating an advanced hematologic malignancy selected from a group consisting of acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to the subject in need thereof the tablet of  claim 49 . 
     
     
         54 . The method of  claim 53 , wherein the advanced hematologic malignancy is acute myelogenous leukemia. 
     
     
         55 . The method of  claim 54 , wherein the acute myelogenous leukemia is relapsed or primary refractory. 
     
     
         56 . The method of  claim 53 , wherein the tablet is administered orally. 
     
     
         57 . The method of  claim 56 , wherein the tablet is administered orally twice daily or once daily. 
     
     
         58 . A method of treating an advanced hematologic malignancy selected from a group consisting of acute myelogenous leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to the subject in need thereof the tablet of  claim 52 . 
     
     
         59 . The method of  claim 58 , wherein the advanced hematologic malignancy is acute myelogenous leukemia. 
     
     
         60 . The method of  claim 59 , wherein the acute myelogenous leukemia is relapsed or primary refractory. 
     
     
         61 . The method of  claim 58 , wherein the tablet is administered orally. 
     
     
         62 . The method of  claim 61 , wherein the tablet is administered orally twice daily or once daily.